Asterias Biotherapeutics (AST) Misses Q1 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. AMZN
5. INTC
6. FTNT
7. EBAY
8. DASH
9. BIIB
10. CART

Go back to Asterias Biotherapeutics (AST) Misses Q1 EPS by 13c

Asterias Biotherapeutics Reports First Quarter Results

May 16, 2016 4:06 PM EDT

FREMONT, Calif., May 16, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2016. The company also announced plans to expand the AST-OPC1 Phase 1/2a trial in spinal cord injury patients following recent clearance for the expansion by the U.S. Food and Drug Administration (FDA) based on the favorable safety profile observed so far with AST-OPC1 in the current study.

"Recent FDA clearance for... More